肺动脉顺应性升高与肺动脉高压生存相关:一项新型网络医学分析
该研究基于美国退伍军人系统数据,利用网络医学框架对右心导管确诊的肺动脉高压患者进行亚组分析,发现肺动脉顺应性(PAC)≥3.0 ml/mm Hg与全因死亡风险降低相关,且在验证队列中亦得到验证,提示PAC可能作为治疗目标。
要点
- PAC≥3.0 ml/mm Hg与肺动脉高压患者全因死亡风险降低独立相关。
- 该保护性关联在毛细血管前肺动脉高压患者中最为显著。
- 研究提示PAC≥3.0 ml/mm Hg可作为未来前瞻性研究的治疗目标。
核心结论
- elevated PAC(≥3.0 ml/mm Hg)是与肺动脉高压患者生存改善相关的重要参数。
研究设计与样本
- 发现队列为mPAP 19-24 mm Hg的完整病例患者(N=4,737),验证队列来自范德堡大学性别平衡的右心导管队列(N=1,514)。
- 连续变量分析纳入mPAP≥19 mm Hg的患者(N=37,744;年龄67.2岁[范围61.7-73.8];96.7%男性;中位随访1,236天[范围570-1,971])。
主要发现
- 在mPAP 19-24 mm Hg患者中识别出21个不同的网络模块,各模块全因死亡率范围为15.9%-61.2%。
- PAC驱动患者分配至生存率较高的模块;在mPAP≥19 mm Hg患者中,PAC≥3.0 ml/mm Hg时调整后全因死亡风险比<1.0,并随PAC增至约7 ml/mm Hg而逐渐降低。
- 验证队列中亦观察到PAC≥3.0 ml/mm Hg与死亡的保护性关联;在毛细血管前肺动脉高压患者中关联最强,发现队列和验证队列中PAC≥3.0 vs <3.0 ml/mm Hg的生存改善分别为41%(95%CI 0.55-0.62;P<0.001)和49%(95%CI 0.38-0.69;P<0.001)。
关键数值与推荐
- PAC≥3.0 ml/mm Hg定义为保护性关联的阈值,对应调整后全因死亡风险比<1.0。
- 毛细血管前肺动脉高压患者中,PAC≥3.0 vs <3.0 ml/mm Hg的生存改善:发现队列41%(95%CI 0.55-0.62;P<0.001),验证队列49%(95%CI 0.38-0.69;P<0.001)。
临床怎么用
- 对于肺动脉高压患者,可考虑将PAC≥3.0 ml/mm Hg作为风险分层和潜在治疗目标的参考指标。
- 未来前瞻性研究应评估通过已验证干预措施达到PAC≥3.0 ml/mm Hg是否能改善生存。
局限性
- 研究为回顾性分析,发现队列以男性为主(96.7%),验证队列性别平衡但样本量较小。
- PAC≥3.0 ml/mm Hg作为治疗目标尚需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Predictors of adverse outcome in pulmonary hypertension (PH) are well established; however, data that inform survival are lacking. Objectives: We aim to identify clinical markers and therapeutic targets that inform the survival in PH. Methods: We included data from patients with elevated mean pulmonary artery pressure (mPAP) diagnosed by right heart catheterization in the U.S. Veterans Affairs system (October 1, 2006-September 30, 2018). Network medicine framework was used to subgroup patients when considering an N of 79 variables per patient. The results informed outcome analyses in the discovery cohort and a sex-balanced validation right heart catheterization cohort from Vanderbilt University (September 24, 1998-December 20, 2013). Measurements and Main Results: From an N of 4,737 complete case patients with mPAP of 19-24 mm Hg, there were 21 distinct subgroups (network modules) (all-cause mortality range = 15.9-61.2% per module). Pulmonary arterial compliance (PAC) drove patient assignment to modules characterized by increased survival. When modeled continuously in patients with mPAP ⩾19 mm Hg (N = 37,744; age, 67.2 yr [range = 61.7-73.8 yr]; 96.7% male; median follow-up time, 1,236 d [range = 570-1,971 d]), the adjusted all-cause mortality hazard ratio was <1.0 beginning at PAC ⩾3.0 ml/mm Hg and decreased progressively to ∼7 ml/mm Hg. A protective association between PAC ⩾3.0 ml/mm Hg and mortality was also observed in the validation cohort (N = 1,514; age, 60.2 yr [range = 49.2-69.1 yr]; 48.0% male; median follow-up time, 2,485 d [range = 671-3,580 d]). The association was strongest in patients with precapillary PH at the time of catheterization, in whom 41% (95% confidence interval, 0.55-0.62; P < 0.001) and 49% (95% confidence interval, 0.38-0.69; P < 0.001) improvements in survival were observed for PAC ⩾3.0 versus <3.0 ml/mm Hg in the discovery and validation cohorts, respectively. Conclusions: These data identify elevated PAC as an important parameter associated with survival in PH. Prospective studies are warranted that consider PAC ⩾3.0 ml/mm Hg as a therapeutic target to achieve through proven interventions.
引用
- Wang RS, Huang S, Waldo SW, et al. Elevated Pulmonary Arterial Compliance Is Associated with Survival in Pulmonary Hypertension: Results from a Novel Network Medicine Analysis. Am J Respir Crit Care Med. 2023. PMID: 37276608. doi:10.1164/rccm.202211-2097OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。